In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
How to Find a Cancer Treatment Trial
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
Featured Clinical Trials Supported by NCI

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 25 for your search:

Cancer Type/Condition:  Rhabdomyosarcoma, child
Stage/Subtype:  recurrent childhood rhabdomyosarcoma
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and under
Sponsor: NICHD
Protocol IDs: PPRU 10762, NCT00491946

Reduced Intensity Transplant Using Extracorporeal Photopheresis

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: ECP RIT, NCT00179790

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 to 17
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLDE225X2104, 2010-019348-37, NCT01125800

To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 20
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: 100220, IND 59,056, NCT01222780

Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 4 to 21
Sponsor: Other
Protocol IDs: 10-096, NCT01294670

Aerosol IL-2 for Pulmonary Metastases

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 12 and over
Sponsor: Other
Protocol IDs: 2010-0700, NCT01590069

Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: PSCI-2003-232, NCT00084695

Radiation Therapy to Treat Musculoskeletal Tumors

Phase: Phase II
Type: Treatment
Status: Active
Age: 25 and under
Sponsor: Other
Protocol IDs: RTSARC, NCT00186992

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 05-122, MSKCC-05122, NCT00445965

10.

MLN8237 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI, Other
Protocol IDs: CDR0000680512, COG-ADVL0921, ADVL0921, NCT01154816

11.

Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Phase: Phase II
Type: Treatment
Status: Active
Age: Under 30
Sponsor: NCI
Protocol IDs: NCI-2011-02607, ARST0921, CDR0000687113, U10CA098543, COG-ARST0921, NCT01222715

12.

Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 30
Sponsor: NCI
Protocol IDs: NCI-2012-00106, ADVL1121, U10CA098543, CDR0000721611, COG-ADVL1121, NCT01502410

13.

Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 15 and over
Sponsor: Other
Protocol IDs: SOL-11130-L, NCI-2012-00052, IRB# 7943, NCT01532687

14.

A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors

Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 40
Sponsor: Other
Protocol IDs: J12106, NCT01804634

15.

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

Phase: Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 03-133, P30CA008748, MSKCC-03133, NCT00089245

16.

Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 3 to 21
Sponsor: NCI, Other
Protocol IDs: CDR0000663520, COG-ADVL0911, ADVL0911, NCT01048892

17.

A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias

Phase: Phase I
Type: Treatment
Status: Active
Age: 4 to 35
Sponsor: NCI
Protocol IDs: 110073, 11-C-0073, NCT01287104

18.

Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 21
Sponsor: NCI
Protocol IDs: 080007, 08-C-0007, NCT01445379

19.

Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 21
Sponsor: Other
Protocol IDs: SorIrin1576, NCT01518413

20.

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 21
Sponsor: Other
Protocol IDs: RADIANT, NCT01625351

21.

A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 1 to 21
Sponsor: Pharmaceutical / Industry
Protocol IDs: 14492, I4J-MC-HHBD, NCT01697514

22.

Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 100
Sponsor: Other
Protocol IDs: EPROST-20110462, NCT01803152

23.

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: CDR0000554417, JHOC-J0685, NA_00003073, J0685, NCT00499733

24.

Auto Transplant for High Risk or Relapsed Solid Tumor

Phase: No phase specified
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: 2011OC057, MT2011-09C, NCT01505569

25.

Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases

Phase: No phase specified
Type: Treatment
Status: Active
Age: 1 to 29
Sponsor: NCI, Other
Protocol IDs: Lung IMRT, NCT01586104

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map